In Brief: Tri-Med Labs
This article was originally published in The Tan Sheet
Executive Summary
Tri-Med Labs: "Serious" deviations from GMP regs were documented by FDA investigators at Tri-Med's Somerset, N.J. facility, FDA says in a March 26 warning letter. The letter cites various problems in the firm's manufacture, processing, packing and holding of various drug products, causing the products to be considered adulterated under the FD&C Act. For example, Tri-vitamin Drops with Fluoride .25 mg Supplement for Infants contains levels of vitamins A and D and ascorbic acid exceeding the label claims...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning